tetano
Editor, Senior Moderator
LONDON (Reuters) - After a lengthy fight, Swiss drugmaker Roche Holding AG said it had agreed to hand over data from all clinical trials of its best-selling flu drug Tamiflu to a group of outside researchers.
Tamiflu has been approved by regulators worldwide and stockpiled by many governments in case of a pandemic, but some scientists claim there is little evidence it works and have lobbied since 2009 for Roche to release all its trial data.
In an email to the Cochrane Collaboration, a non-profit group that reviews trial data to assess the value of drugs, Roche said it would provide clinical study reports on all the 74 studies into its medicine, over the next few months.
A copy of the April 2 email was supplied to Reuters on Thursday.
http://www.chicagotribune.com/health/sns-rt-us-roche-tamiflubre93314b-20130404,0,4723111.story
Tamiflu has been approved by regulators worldwide and stockpiled by many governments in case of a pandemic, but some scientists claim there is little evidence it works and have lobbied since 2009 for Roche to release all its trial data.
In an email to the Cochrane Collaboration, a non-profit group that reviews trial data to assess the value of drugs, Roche said it would provide clinical study reports on all the 74 studies into its medicine, over the next few months.
A copy of the April 2 email was supplied to Reuters on Thursday.
http://www.chicagotribune.com/health/sns-rt-us-roche-tamiflubre93314b-20130404,0,4723111.story